RT Journal Article
T1 Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.
A1 Troya, Jesús
A1 Ryan, Pablo
A1 Ribera, Esteban
A1 Podzamczer, Daniel
A1 Hontañón, Victor
A1 Terrón, Jose Alberto
A1 Boix, Vicente
A1 Moreno, Santiago
A1 Barrufet, Pilar
A1 Castaño, Manuel
A1 Carrero, Ana
A1 Galindo, María José
A1 Suárez-Lozano, Ignacio
A1 Knobel, Hernando
A1 Raffo, Miguel
A1 Solís, Javier
A1 Yllescas, María
A1 Esteban, Herminia
A1 González-García, Juan
A1 Berenguer, Juan
A1 Imaz, Arkaitz
K1 Benzoxazinas
K1 Recuento de Linfocito CD4
K1 Didesoxinucleósidos
K1 Combinación de medicamentos
K1 Efectos colaterales y reacciones adversas relacionados con medicamentos
K1 Estudios de seguimiento
K1 Tasa de filtración glomerular
K1 Infecciones por Vih
K1 VIH-1
K1 Humanos
K1 Análisis de intención de tratar
K1 Lamivudine
K1 Lípidos
K1 Masculino
K1 ARN
K1 Estudios retrospectivos
K1 Rilpivirine
AB OBJECTIVESBased on data from clinical practice, we evaluated the effectiveness and safety of switching to abacavir/lamivudine plus rilpivirine (ABC/3TC+RPV) treatment in virologically suppressed HIV-1-infected patients.METHODSWe performed a multicenter, non-controlled, retrospective study of HIV-1-infected patients who switched treatment to ABC/3TC+RPV. Patients had an HIV-RNA <50 copies/mL for at least 24 weeks prior to changing treatments. The primary objective was HIV-1 RNA <50 copies/mL at week 48. Effectiveness was analyzed by intention-to-treat (ITT), missing = failure and on-treatment (OT) analyses. The secondary objectives analyzed were adverse effects changes in renal, hepatic or lipid profiles, changes in CD4+ cell count and treatment discontinuations.RESULTSOf the 205 patients included, 75.6% were men and the median age was 49. At baseline, before switching to ABC/3TC+RPV, median time since HIV diagnosis was 13.1 years, median time with undetectable HIV-1 RNA was 6.2 years and median time of previous antiretroviral regimen was 3.1 years (48.3% patients were taking efavirenz and ABC/3TC was the most frequent backbone coformulation in 69.7% of patients). The main reasons for switching were drug toxicity/poor tolerability (60.5%) and simplification (20%). At week 48, the primary objective was achieved by 187 out of 205 (91.2%) patients by ITT analysis, and 187 out of 192 (97.4%) patients by OT analysis. The CD4+ lymphocyte count and CD4+ percentage increased significantly from baseline to week 48 by a median of 48 cells/μL (-50 to 189) and 1.2% (-1.3% to 4.1%), respectively, P<0.001. Thirty-eight adverse events (AE) were detected in 32 patients. Of these, 25 had no clear association with treatment. Three patients interrupted therapy due to AE. We observed a decrease in all lipid parameters, P<0.001, and a slight improvement in the glomerular filtration rate, P<0.01. Therapy was considered to have failed in 18 patients owing to virological failure (5 [2.4%]), toxicity/poor tolerability (4 [2%]), clinical decision (3 [1.5%]), loss to follow-up (3 [1.5%]), death (1 [0.5%]), and no clinical data (2 [1%]).CONCLUSIONSThe results of this study confirms that ABC/3TC+RPV is an effective, safe, and cost-effective option for the treatment of patients with virologically stable HIV-1 infection.
PB Public Libray of Science
YR 2016
FD 2016-10-11
LK http://hdl.handle.net/10668/2520
UL http://hdl.handle.net/10668/2520
LA en
NO Troya J, Ryan P, Ribera E, Podzamczer D, Hontañón V, Terrón JA, et al. Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study. PLoS ONE. 2016; 11(10):e0164455
NO JOURNAL ARTICLE;
DS RISalud
RD Apr 12, 2025